Phase 3 trial of Obeticholic acid in NASH patients with cirrhosis.

Trial Profile

Phase 3 trial of Obeticholic acid in NASH patients with cirrhosis.

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 10 May 2017

At a glance

  • Drugs Obeticholic acid (Primary)
  • Indications Fibrosis; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2017 New trial record
    • 04 May 2017 According to an Intercept Pharmaceuticals media release, company plans to initiate this trial during 2H 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top